Drugs / VX-522
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05668741 | Feb 2023 → Apr 2026 overdue | cystic fibrosis | Vertex Pharmaceuticals Incorporated | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2022-12-21 | SpliSense Ltd. | Regulatory Vertex and SpliSense Tackle CF with Novel Inhaled mRNA Approaches splisense.com ↗
More quietly on Monday, Vertex announced the clearance of an Investigational New Drug application for VX-522 , an mRNA therapy designed to treat the underlying cause of cystic fibrosis lung disease. |
| 2022-12-12 | Vertex Pharmaceuticals Incorporated | Regulatory Vertex Announces Investigational New Drug (IND) Application for VX-522, mRNA Therapy for People With Cystic Fibrosis, Cleared by FDA vrtx.com ↗
Clearance of the IND represents a pivotal turning point in reaching the remaining ~5,000 people with CF who are still waiting for a medicine to treat the underlying cause of their disease |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2022-12-21 | SpliSense Ltd. | Vertex and SpliSense Tackle CF with Novel Inhaled mRNA Approaches splisense.com ↗ |
| 2022-12-12 | Vertex Pharmaceuticals Incorporated | Vertex Announces Investigational New Drug (IND) Application for VX-522, mRNA Therapy for People With Cystic Fibrosis, Cleared by FDA vrtx.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VX-522 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05668741 ↗ |
| Modality | Messenger RNA (mRNA) | “VX-522 mRNA therapy” NCT05668741 ↗ |
| Route | Inhaled | “Oral inhalation using nebulizer.” NCT05668741 ↗ |